These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 26410247)

  • 41. Effect of formulary policy decisions on antimicrobial drug utilization in British Columbia.
    Marra F; Patrick DM; White R; Ng H; Bowie WR; Hutchinson JM
    J Antimicrob Chemother; 2005 Jan; 55(1):95-101. PubMed ID: 15590717
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The case for a value-based formulary: striving for total lowest net cost.
    Weart W; Bauman GR
    Manag Care Interface; 2007 Apr; 20(4):42-7. PubMed ID: 17474330
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effects of coxib formulary restrictions on analgesic use and cost: regional evidence from Canada.
    Marshall DA; Willison DJ; Grootendorst P; LeLorier J; Maclure M; Kulin NA; Sheehy OE; Warren L; Sykora K; Rahme E
    Health Policy; 2007 Nov; 84(1):1-13. PubMed ID: 17570558
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [A proposed open formulary for a managed care program in Mexico. The Therapeutic and Pharmacological Committee of Mexico].
    Salud Publica Mex; 1999; 41(1):27-41. PubMed ID: 10081332
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of funding policy changes and health warnings on the use of erythropoiesis-stimulating agents.
    Weir MA; Gomes T; Winquist E; Juurlink DN; Cuerden MS; Mamdani M
    J Oncol Pract; 2012 May; 8(3):179-83. PubMed ID: 22942813
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Developing a harmonized heat warning and information system for Ontario: a case study in collaboration.
    Henderson D; Aubin L; Behan K; Chen H; Doyle H; Gower S; MacDonald M; Mee C; Richardson GRA; Rochon G; Shnabel M; Storfer J; Yagouti A; Yusa A
    Can J Public Health; 2020 Jun; 111(3):426-432. PubMed ID: 32524507
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Consider potential for drug interactions during formulary review.
    Chan LN
    Am J Health Syst Pharm; 2000 Feb; 57(4):391-2. PubMed ID: 10714978
    [No Abstract]   [Full Text] [Related]  

  • 48. Health Canada's use of its priority review process for new drugs: a cohort study.
    Lexchin J
    BMJ Open; 2015 May; 5(5):e006816. PubMed ID: 25967989
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Academy of Managed Care Pharmacy Format for Formulary Submissions: an evolving standard--a Foundation for Managed Care Pharmacy Task Force report.
    Fry RN; Avey SG; Sullivan SD
    Value Health; 2003; 6(5):505-21. PubMed ID: 14627057
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Principles for evidence-based drug formulary policy.
    Simon GE; Psaty BM; Hrachovec JB; Mora M
    J Gen Intern Med; 2005 Oct; 20(10):964-8. PubMed ID: 16191151
    [TBL] [Abstract][Full Text] [Related]  

  • 51. FDA boxed warnings: how to prescribe drugs safely.
    O'Connor NR
    Am Fam Physician; 2010 Feb; 81(3):298-303. PubMed ID: 20112888
    [TBL] [Abstract][Full Text] [Related]  

  • 52. FDA warning and removal of rosiglitazone from VA national formulary.
    Aspinall SE; Zhao X; Good CB; Stone RA; Smith KJ; Cunningham FE
    Am J Manag Care; 2013 Sep; 19(9):748-58. PubMed ID: 24304257
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An analysis of legal warnings after drug approval in Thailand.
    Sriphiromya P; Theeraroungchaisri A
    Regul Toxicol Pharmacol; 2015 Feb; 71(1):108-13. PubMed ID: 25445000
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Drug-review deadlines and safety problems.
    Carpenter D; Zucker EJ; Avorn J
    N Engl J Med; 2008 Mar; 358(13):1354-61. PubMed ID: 18367738
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The use of research abstracts in formulary decision making by the Joint Oncology Drug Review of Canada.
    Weizman AV; Griesman J; Bell CM
    Appl Health Econ Health Policy; 2010; 8(6):387-91. PubMed ID: 21043540
    [TBL] [Abstract][Full Text] [Related]  

  • 56. How safe are new drugs? Market withdrawal of drugs approved in Canada between 1990 and 2009.
    Lexchin J
    Open Med; 2014; 8(1):e14-9. PubMed ID: 25009681
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Factors associated with prescribing restriction on oncology formulary drugs in Malaysia.
    Fatokun O; Olawepo MN
    Int J Clin Pharm; 2016 Oct; 38(5):1075-9. PubMed ID: 27586371
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adherence to the Grampian joint drug formulary in general practice.
    Stewart D; Milne K; Krska J; Downie G
    J Clin Pharm Ther; 1996 Apr; 21(2):79-82. PubMed ID: 8809643
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Drug Safety Data Curation and Modeling in ChEMBL: Boxed Warnings and Withdrawn Drugs.
    Hunter FMI; Bento AP; Bosc N; Gaulton A; Hersey A; Leach AR
    Chem Res Toxicol; 2021 Feb; 34(2):385-395. PubMed ID: 33507738
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Review of yellow cards (1986): report to the Committee on the Safety of Medicines.
    Bem JL; Breckenridge AM; Mann RD; Rawlins MD
    Br J Clin Pharmacol; 1988 Dec; 26(6):679-89. PubMed ID: 3242573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.